Pulocimab
drugOn this page
Also known as AK-109Ak109
Summary
Pulocimab (CHEMBL4802188) is a phase-3 clinical-stage antibody targeting KDR; indicated across 2 conditions including adenocarcinoma and neoplasm.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Targets: 1 (KDR)
- Indications: 2 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4802188 |
| Name | Pulocimab |
| Type | Antibody |
| Max phase | 3 |
Also known as: AK-109, Ak109, AK109, Pulocimab, PULOCIMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| KDR | kinase insert domain receptor | Binding | 9.96 | 1.1% | P35968 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): KDR.
Top Reactome pathways
7 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Neuropilin interactions with VEGF and VEGFR | 1 | KDR |
| VEGF binds to VEGFR leading to receptor dimerization | 1 | KDR |
| Integrin cell surface interactions | 1 | KDR |
| VEGFA-VEGFR2 Pathway | 1 | KDR |
| VEGFR2 mediated cell proliferation | 1 | KDR |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | 1 | KDR |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | 1 | KDR |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| angiogenesis | 1 |
| ovarian follicle development | 1 |
| branching involved in blood vessel morphogenesis | 1 |
| vasculogenesis | 1 |
| positive regulation of protein phosphorylation | 1 |
| positive regulation of endothelial cell proliferation | 1 |
| lymph vessel development | 1 |
| positive regulation of mesenchymal cell proliferation | 1 |
| epithelial cell maturation | 1 |
| endocardium development | 1 |
| endothelium development | 1 |
| cell surface receptor protein tyrosine kinase signaling pathway | 1 |
| positive regulation of cell population proliferation | 1 |
| regulation of cell shape | 1 |
| mesenchymal cell proliferation | 1 |
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| adenocarcinoma | 3 | MONDO:0004970 | MONDO:0003219 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06341335 | PHASE3 | RECRUITING | A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma |
| NCT04982276 | PHASE1/PHASE2 | RECRUITING | A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma |
| NCT05142423 | PHASE1/PHASE2 | RECRUITING | A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors |
| NCT04547205 | PHASE1 | COMPLETED | A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
161 molecules share ≥1 primary target. Top 60 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| GENTIAN VIOLET | ChEMBL + PubChem | Phase 4 (approved) | KDR |
| PAZOPANIB | ChEMBL + PubChem | Phase 4 (approved) | KDR |
| REGORAFENIB | ChEMBL + PubChem | Phase 4 (approved) | KDR |
| ABEMACICLIB | ChEMBL | Phase 4 (approved) | KDR |
| ABROCITINIB | ChEMBL | Phase 4 (approved) | KDR |
| ACALABRUTINIB | ChEMBL | Phase 4 (approved) | KDR |
| ALECTINIB | ChEMBL | Phase 4 (approved) | KDR |
| AUROTHIOGLUCOSE | ChEMBL | Phase 4 (approved) | KDR |
| AXITINIB | ChEMBL | Phase 4 (approved) | KDR |
| BRIGATINIB | ChEMBL | Phase 4 (approved) | KDR |
| CABOZANTINIB | ChEMBL | Phase 4 (approved) | KDR |
| CABOZANTINIB S-MALATE | ChEMBL | Phase 4 (approved) | KDR |
| CERITINIB | ChEMBL | Phase 4 (approved) | KDR |
| CRIZOTINIB | ChEMBL | Phase 4 (approved) | KDR |
| DASATINIB | ChEMBL | Phase 4 (approved) | KDR |
| ENASIDENIB | ChEMBL | Phase 4 (approved) | KDR |
| ENTRECTINIB | ChEMBL | Phase 4 (approved) | KDR |
| ERDAFITINIB | ChEMBL | Phase 4 (approved) | KDR |
| ERLOTINIB | ChEMBL | Phase 4 (approved) | KDR |
| ESTRAMUSTINE | ChEMBL | Phase 4 (approved) | KDR |
| FEDRATINIB | ChEMBL | Phase 4 (approved) | KDR |
| FOSTAMATINIB DISODIUM | ChEMBL | Phase 4 (approved) | KDR |
| FRUQUINTINIB | ChEMBL | Phase 4 (approved) | KDR |
| FUTIBATINIB | ChEMBL | Phase 4 (approved) | KDR |
| GEFITINIB | ChEMBL | Phase 4 (approved) | KDR |
| GLAFENINE | ChEMBL | Phase 4 (approved) | KDR |
| HEXACHLOROPHENE | ChEMBL | Phase 4 (approved) | KDR |
| IBRUTINIB | ChEMBL | Phase 4 (approved) | KDR |
| IMATINIB | ChEMBL | Phase 4 (approved) | KDR |
| INDIGOTINDISULFONATE | ChEMBL | Phase 4 (approved) | KDR |
| INFIGRATINIB | ChEMBL | Phase 4 (approved) | KDR |
| ISOXICAM | ChEMBL | Phase 4 (approved) | KDR |
| LENVATINIB | ChEMBL | Phase 4 (approved) | KDR |
| MEBENDAZOLE | ChEMBL | Phase 4 (approved) | KDR |
| MESALAMINE | ChEMBL | Phase 4 (approved) | KDR |
| MIDOSTAURIN | ChEMBL | Phase 4 (approved) | KDR |
| NERATINIB | ChEMBL | Phase 4 (approved) | KDR |
| NICLOSAMIDE | ChEMBL | Phase 4 (approved) | KDR |
| NINTEDANIB | ChEMBL | Phase 4 (approved) | KDR |
| NINTEDANIB ESYLATE | ChEMBL | Phase 4 (approved) | KDR |
| NOVOBIOCIN | ChEMBL | Phase 4 (approved) | KDR |
| OLMUTINIB | ChEMBL | Phase 4 (approved) | KDR |
| OLSALAZINE | ChEMBL | Phase 4 (approved) | KDR |
| OSIMERTINIB | ChEMBL | Phase 4 (approved) | KDR |
| PEXIDARTINIB | ChEMBL | Phase 4 (approved) | KDR |
| PHENYL AMINOSALICYLATE | ChEMBL | Phase 4 (approved) | KDR |
| PIPERAZINE | ChEMBL | Phase 4 (approved) | KDR |
| PONATINIB | ChEMBL | Phase 4 (approved) | KDR |
| QUIZARTINIB | ChEMBL | Phase 4 (approved) | KDR |
| SELPERCATINIB | ChEMBL | Phase 4 (approved) | KDR |
| SORAFENIB | ChEMBL | Phase 4 (approved) | KDR |
| SORAFENIB TOSYLATE | ChEMBL | Phase 4 (approved) | KDR |
| STIRIPENTOL | ChEMBL | Phase 4 (approved) | KDR |
| SUNITINIB | ChEMBL | Phase 4 (approved) | KDR |
| SUNITINIB MALATE | ChEMBL | Phase 4 (approved) | KDR |
| TIVOZANIB | ChEMBL | Phase 4 (approved) | KDR |
| TOFACITINIB | ChEMBL | Phase 4 (approved) | KDR |
| UPADACITINIB | ChEMBL | Phase 4 (approved) | KDR |
| VANDETANIB | ChEMBL | Phase 4 (approved) | KDR |
| VEMURAFENIB | ChEMBL | Phase 4 (approved) | KDR |
Related Atlas pages
- Genes: KDR
- Diseases: adenocarcinoma
- Drugs: Pazopanib, Regorafenib, Abemaciclib, Abrocitinib, Acalabrutinib, Alectinib, Aurothioglucose, Axitinib, Brigatinib, Cabozantinib, Ceritinib, Crizotinib, Dasatinib, Enasidenib, Entrectinib, Erdafitinib, Erlotinib, Estramustine, Fedratinib, Fruquintinib, Futibatinib, Gefitinib, Glafenine, Hexachlorophene, Ibrutinib, Imatinib, Infigratinib, Isoxicam, Lenvatinib, Mebendazole, Mesalamine, Midostaurin, Neratinib, Niclosamide, Nintedanib, Novobiocin, Olmutinib, Olsalazine, Osimertinib, Pexidartinib, Phenyl Aminosalicylate, Piperazine, Ponatinib, Quizartinib, Selpercatinib, Sorafenib, Stiripentol, Sunitinib, Tivozanib, Tofacitinib, Upadacitinib, Vandetanib, Vemurafenib